Kornimate/medical-research-clean huggingface dataset:
study of the prevalence of diabetes and pre-diabetes in réunion island

Conditions: Diabetes

Summary: in view of the new priority given to diabetes in réunion and the implementation of an ambitious plan to combat the disease at regional level, which includes the identification and management of pre-diabetes, the need for up-to-date data on the extent of these 2 diseases (diabetes and pre-diabetes) has become essential. these two diseases have known risk factors: age, overweight, obesity, high waist circumference, family history, hypertension, eating habits and physical activity, all of which form part of a risk score for developing diabetes: the findrisk recommended by the haute autorité de santé for identifying people at risk of diabetes. given the specific population characteristics of réunion compared with finland, where this score has been validated, it would seem important to be able to measure these risk indicators in the population as a function of carbohydrate status in order to check that the proposed thresholds are appropriate for the population of réunion. finally, cardiovascular risk has been described as early as the pre-diabetes stage. given the young age of onset of diabetes in réunion and the high proportion of diagnoses of diabetes made following the occurrence of a cardiovascular complication, the study of the prognosis of carbohydrate status on the occurrence of complications using the social security information system will be offered on a voluntary basis to study subjects (via a probabilistic social security link).


Eligibility criteria:
inclusion criteria: * have lived in réunion island for at least one year * be aged between 18 and 75 * affiliated to or benefiting from a social security scheme * free, informed and signed consent exclusion criteria: * no main residence on the island or fixed address for at least one year on the island * participation in experimental research * pregnant women * adults under guardianship or legal protection * not understanding french
collagen analysis and genetic analysis of families with tendency to hernias

Conditions: Hernia

Summary: analysis of collagen subtype subcutaneously and genetic analysis of patients from families with a tendency to hernias. furthermore circulating biomarkers and biomarkers extracted from the subcutaneously tissue such as mmp's (matrix metallo proteinases) and timp's (tissue inhibitor of metallo proteinases) will be measured.

research has shown relationship between hernias and collagen subtype i/iii ratio, biomarkers such as mmp's timp's and other diseases such as ehlers-danlos, marfans syndrome, aaa (abdominal aortic aneurysms), diverticulosis and rectal prolapse. furthermore has research raised hypothesis about inheritance of hernias. the investigators are performing genetic examination combined with analysis of collagen and biomarkers on patients belonging to families with tendency to hernias. other examinations performed on the patients enrolled in this study: * ultrasound (us) examination of the abdominal aorta to discover possible abdominal aortic aneurysms. * beightons score to evaluate the degree of joint hypermobility.

Eligibility criteria:
inclusion criteria: * adults over 18 years * adults must be members of a family where there are presence of hernias in minimum generation. exclusion criteria: * infections * pregnant * mentally ill patients

Keywords: ventral inguinal hernia inheritance genetics
the effect of probiotics on response to therapy and on adverse effect in patients treated with colchicine for familial mediterranean fever.

Conditions: Familial Mediterranean Fever (FMF )

Summary: colchicine is the drug of choice to treat patients with familial mediterranean fever (fmf ), some of the patients treated with colchicine may suffer from gastrointestinal (git) adverse effect such as diarrhea and abdominal pain especially in the higher dose. 5-10% of the patients with fmf that have been treated with colchicine may have partial or no response to this therapy. aim of our study: the aim of our study is :.1to evaluate the efficacy of probiotics in reducing the number of adverse effect in patients with fmf that are being treated with colchicine and suffering from git adverse effect. .2 to evaluate the efficacy of probiotics in reducing the number of fmf attacks in children with fmf that has been treated with colchicine with only partial response. methods: the study will be done among children (5-17 years old) with fmf that are currently followed in the pediatric rheumatology clinic at mayer children hospital israel haifa that are being treated with colchicine and suffering from either git adverse effect or partial response to colchicine. the study is design to be double blind placebo control, in the first 3 month patients will be with no therapy and will be required to record all there fmf episodes and their git adverse effect, in the second period the patients will be randomly divided into two groups 1.patients that will received placebo (group 1) and the 2. probiotics group - patients will received probiotics (bio -25 including 11 types of bacteria l.acidophilus, b.bifidum , l.rhamnosus, l.lactis, l.casei, b.breve, b.thermophilus, b.longum, l.paracseis, l.plantarum, b.infantis), both for three month, during this period patient will be required to record their gastrointestinal symptoms and other symptoms that may be related to fmf.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of fmf * age 5-18 years * colchicine therapy * gastrointestinal adverse effect or recurrent fmf attacks on colchicine exclusion criteria: • severe immune deficiency

Keywords: familial mediterranean fever (fmf), probiotics
dual energy cone-beam computed tomography (de-cbct) assessment of jaw bone density

Conditions: Dental Diseases

Summary: current radiologic imaging modalities used in dentistry provide information on the morphology of the hard tissues. additional information on the density of bone has practical relevance, for example, in dental implant treatment planning, where local bone quality is a known strong predictor of successful implant osseointegration. the dual-energy cone beam computed tomography (de-cbct) device is designed to overcome limitations of traditional imaging and will provide assessment of jaw bone density in additional to morphological information. this clinical trial will examine the application of de-cbct to assess jaw bone density and compare hounsfield units (hu) values with multidetector ct, an established standard for assessing bd.

this is a single center, open-label trial, designed to enroll 24 patients. both, the researcher and the subject know the treatment the participant is receiving. to evaluate the effectiveness and safety of de-cbct to evaluate jaw bone density and compare hu values with those of multidetector ct, an established standard for assessing bd. the study is based on two visits (visit 1 and visit 2) • day 0 (enrollment): subject is queried for inclusion/exclusion criteria and informed about the study. if he/she agrees to participate, inclusion/exclusion criteria and informed consent will be documented. an imaging stent, which bears radiopaque markers, will be also created for each patient. • visit 1: inclusion/exclusion criteria will be reconfirmed and the de-cbct imaging will be completed. • visit 2 (no more than 30 days since the enrollment): inclusion/exclusion criteria will be reconfirmed and mdct imaging completed. - depending on availability of scheduling on mdct unit, visit 2 may occur on the same day as visit 1.

Eligibility criteria:
inclusion criteria: 1. patients who need x-ray imaging for dental treatment planning and/or diagnosis 2. males or females aged older than 21 3. can follow instructions to be positioned into the ct scanner 4. can remain physically immobile during the ct scan acquisition 5. voluntarily sign and date the informed consent exclusion criteria: 1. pregnancy 2. patients who are unable to comprehend the risks of the study to provide informed consent 3. extensive dental restorations, maxillofacial prosthesis, or orthopedic hardware that likely may cause artifacts and degrade quality, as determined by the study radiologists

Keywords: cone beam computed tomography, dual-energy ct
self- sampling in cervical cancer routine screening

Conditions: Cervical Cancer Screening

Summary: self-sampling in cervical cancer routine screening (falcon) -study implements a self-sampling option for the non-attendees of the national cervical cancer screening program in the wellbeing services county of pirkanmaa. hpv primary testing is currently preferred method for cervical cancer screening. the hpv-dna self-sampling has been shown to have screening performance equal to that of provider-obtained samples. in 2024, those turning 30, 35, 40, 45, 50, 55, 60, or 65 had the opportunity to participate in the falcon study if they do not respond to the first invitation to cervical cancer screening. from march 2025 also women living in kanta-häme, central finland, päijät-häme, and ostrobothnia can take part to the study. the main objective of the falcon study is to increase the current coverage of the cervical cancer screening program in the pirkanmaa, kanta-häme, central finland, päijät-häme, and ostrobothnia region and assess how acceptable self-sampling is for women.


Eligibility criteria:
inclusion criteria: * women that do not respond to the first national cervical cancer screening invitation in 2024 and 2025 and to whom the reminder letter is sent to. * birth cohorts of women who will turn in screening year: 30, 35, 40, 45, 50, 55, 60 or 65 years old. exclusion criteria: * women who do not belong to the screening year 2024 or 2025 invitation birth cohorts.
safety aid reduction treatment for ptsd among veterans

Conditions: Stress Disorders, Post-Traumatic

Summary: the purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (start) among veterans with posttraumatic stress disorder (ptsd). it is hypothesized that start will be acceptable, feasible, and will lead to reductions in ptsd symptom severity immediately and over time.

rates of posttraumatic stress disorder (ptsd) among military personnel have surged in recent years. in response, the department of veterans affairs (va) has launched nationwide training initiatives to disseminate two ptsd treatments with strong empirical support: prolonged exposure (pe) therapy and cognitive processing therapy (cpt). despite the well-documented effectiveness of pe and cpt, only a minority of veterans with ptsd initiate these trauma-focused treatments. one approach to addressing ptsd in a non-trauma-focused fashion is to utilize empirically supported treatments focused on safety aid reduction. safety aids are maladaptive cognitive and/or behavioral strategies designed to prevent, avoid, or alleviate anxiety. initially introduced as a way to explain how pathological anxiety can persist despite repeated exposure to feared stimuli, safety aids have been found to play a critical role in the etiology and maintenance of various anxiety and related conditions including ptsd. importantly, a separate line of research suggests that safety aids are amenable to change through cognitive behavioral interventions. although promising, these trials did not include patients with ptsd. in this context, the purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (start) for ptsd. participants will include veterans with a diagnosis of ptsd who decline to participate in evidence-based psychotherapies (ebps) for ptsd, namely pe or cpt. it is hypothesized that start will be acceptable, feasible, and will lead to reductions in ptsd symptom severity immediately and over time.

Eligibility criteria:
inclusion criteria: * veterans receiving care at new orleans va * veterans with diagnosis of ptsd who decline trauma focused treatment exclusion criteria: * substance dependence requiring detoxification * active psychosis * uncontrolled bipolar disorder * severe suicidal intent requiring hospitalization * current engagement in psychotherapy

Keywords: safety aid treatment posttraumatic stress disorder veteran
a study of duration of maintained efficacy in rheumatoid arthritis (ra) patients off treatment with mra(a development code of tocilizumab, an anti il-6 receptor monoclonal antibody.)

Conditions: Rheumatoid Arthritis

Summary: a 52-week follow up study to investigate the duration of maintenance of efficacy in patients with ra and achieved low disease activity in clinical trials of mra and stopped the treatment


Eligibility criteria:
inclusion criteria: * patients who achieved das28 of \< 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies. exclusion criteria: * patients who receive dmards or immunosuppressants between the last observation in a previous studies and the first observation in this study
changes of endothelial function before and after dsa in patients with diabetes

Conditions: Diabetes

Summary: endothelial dysfunction is the early step of atherosclerosis. therefore, the investigators hypothesize that digital subtraction angiography (dsa) can damage endothelial function. in this study, the investigators will select 200 diabetic patients who have a dsa for diabetic foot screening. also, the investigators will select 100 healthy subjects as controls. the endothelial function will be determined by high resolution ultrasound before and after dsa. the investigators will observe the changes of endothelial function after dsa assay.


Eligibility criteria:
inclusion criteria: * patients with diabetic foot * age 40 to 70 years old exclusion criteria: * heart failure * renal failure * acute infection

Keywords: diabetic foot digital subtraction angiography endothelial function patients with diabetes age 40 to 70 years old endothelial function are determined
differences in the severity of diabetic neuropathy based on electromyography in type 2 diabetes mellitus patients with and without comorbidities

Conditions: Diabetic Neuropathies

Summary: the goal of this clinical trial is to learn the differences severity level of diabetic neuropathy based on electromyelography in type ii diabetic patient with and without comorbidities. the main questions of this study: 1. what is the electromyography result in type ii diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 2. is there any differences in electromyography result in type ii diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 3. is there any association between distal latency with nerve conduction velocity in type ii diabetic patient with and without comorbidities? 4. is there any association between distal latency with amplitude in type ii diabetic patient with and without comorbidities? 5. is there any differences on diabetic neuropathy severity based on age, height, and a1c levels in type ii diabetic patient with and without comorbidities? researchers will collect information based on hospital registry as secondary data of in type ii diabetic patient with and without comorbidities. the data consist of demographic data, clinical presentation, laboratory, and electromyography were collected from hospital registry by reviewing medical record. then, the data was analyzed by using ibm spss statistics v26.


Eligibility criteria:
inclusion criteria: * diabetic neuropathy patient who classified as distal symmetrical polyneuropathy * diabetic neuropathy patient who has no comorbidities * diabetic neuropathy patient who has hypertension * diabetic neuropathy patient who has hypertension and dyslipidemia exclusion criteria: * diabetic neuropathy patient with history of chemotherapy * diabetic neuropathy patient with history of hernia nucleus pulposus * diabetic neuropathy patient with history of ckd stage v or on routine dyalisis * missing data on medical record

Keywords: type ii diabetic mellitus diabetic neuropathy electromyography
comparison of orcinoside with placebo in treatment of mdd

Conditions: Major Depressive Disorder (MDD)

Summary: the purpose of this study is to determine whether orcinoside capsule in different doses are effective in the treatment of depression. and to explore the preliminary information of safety and efficacy of orcinoside capsule in the chinese patients with depression.


Eligibility criteria:
inclusion criteria: * adult with primary diagnosis of major depressive disorder based on the criteria of dsm-iv-tr, single episode or recurrent episode, not accompanied with psychotic symptoms. coding of diagnosis included: 296.21 mdd single episode, mild 296.22 mdd single episode, moderate 296.31 mdd recurrent episode, mild 296.32 mdd recurrent episode, moderate * the subject is an outpatient. * the subject is a man or woman,aged≥18 and ≤65 years. * the total score of hamd-17 is ≥18 and ≤24 in both screening visit and baseline visit. * the subject is willing to take birth control measures during study period and one month after study. * the subject understands and consents to takes part in this clinical trials. the subjects should sign informed consent. exclusion criteria: * the subject has a significant risk of suicide according to the investigator's opinion or has a score ≥3 on item 3(suicide assessment) of the hamd or has made a suicide attempt. * the subject has a current dsm-ⅳ-tr axisⅰpsychiatric diagnosis other than depression. * when the hamd17 score of baseline visit compares with the screening visit, the decreasing rate is ≥25%. * the subject has a current diagnosis or history of depression due to any other psychotic disorder or a general medical condition, bipolar disorder, or depression accompanied with psychotic symptoms. * any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction), blood,or other medical disease. had a history of seizure disorder or other brain organic disorders. * the subject has a diagnosis of alcohol or other substance abuse or dependence at least 1 years prior to the baseline visit. * known hypersensitivity to common curculigo rhizome or other drugs. * women who were pregnant, breast-feeding, or planning to become pregnant during study. men who have request to fertility within half of year. * clinically significant electrocardiographic(ecg) abnormalities or abnormal laboratory values(eg. hepatic function above 1.5 times of clinical toplimit, renal function above toplimit, blood glucose above toplimit, cardiac troponin abnormal, thyroid gland examine index significantly abnormal). * the subject uses antidepressant drug normally before 2 weeks of screening, and stops using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more than 2 weeks, fluoxetine more than 1 month). * the subject has accepted electroconvulsive therapy within 3months. * the subject has accepted system psychotherapy within 3 months. * the compliance of the subject is poor. * the subject has participated in a drug clinical trial within 30 days before screening. * the investigator think the subject is unsuitable to enrol in this clinical trial.
antibiotic elution after two-stage knee revision

Conditions: Periprosthetic Knee Infection

Summary: the goal of this observational study is to monitor the eluted antibiotic concentrations of gentamicin and vancomycin by a static knee cement spacer in patients being treated for periprosthetic infections of the knee. the main question aims to answer if eluted antibiotics are in a therapeutic range for treatment at sight of infection. secondarily, local antibiotic concentrations are compared with systemic blood levels, as are systemically applied antibiotics compared to intra-articular concentrations. intra-articular samples are collected over a 72 hour postoperative period.

the present study moinitors antibiotic concentrations eluted by a static cement knee spacer as two-stage revision treatment of a knee pji. the static cement spacer consists of copal g+v cement containing 2g of vancomycin and 0.5g of gentamicin. microdialysis is used as a technique for continuous extra cellular sample collection directly from the knee joint cavity. it is implemented guided by a drainage tube during the surgery to remove the infected prosthesis and implement the spacer. over a 72 hour period samples directly from the knee joint are generated continiously. these are analyzed for the eluded antibiotic concentrations of gentamicin and vancomycin from the knee spacer. once every 24 hours venous blood samples were collected as well and analyzed for gentamicin and vancomycin and also systemically applied antibiotics (a.e. cefuroxim, clindamycin).

Eligibility criteria:
inclusion criteria: * clinical indication for a two-staged revision of a knee pji * approval for surgery by the orthopedic and anesthesiologic departments * being over 18 years of age * written, informed consent after detailed patient information about the study protocol and possible study-dependent risks exclusion criteria: * known allergies to the antibiotics gentamicin and vancomycin contained in the spacer

Keywords: two-stage exchange infection arthroplasty pji microdialysis minimal inhibitory concentration bone cement treatment monitoring
efficacy of pramipexole extended release in the treatment of essential tremor

Conditions: Essential Tremor

Summary: aim of the study is to perform a double-blind, crossover, placebo-controlled multicenter study evaluating the efficacy of pramipexole on essential tremor.

essential tremor is one of the most common movement disorders with the prevalence of 3-5% among the elderly population. although its main clinical feature is the bilateral, predominantly postural-kinetic tremor, newer studies suggest that et is a spectrum of clinical features with both motor and nonmotor elements not homogeneously distributed. despite its high occurrence, the pharmacological treatment of et is limited. although the mainline drugs, propranolol and primidone, can provide good clinical benefit in a portion of cases, \>50% of the patients stop the medication due to inefficacy or side-effects. hypotension, dizziness, bradycardia, cognitive impairment, fatigue and erectile dysfunction are the most common side-effects contributing to medication discontinuation. in an open-label pilot study, the investigators previously demonstrated that 2.1 mg/day pramipexole extended-release improved both the severity of tremor (by 52%) and health-related quality of life. the present study aims to confirm this hypothesis in a double-blind, crossover, placebo-controlled multicenter study.

Eligibility criteria:
inclusion criteria: * diagnosis of et has to be unambiguous based on the clinical diagnostic criteria. * tremor has to be severe enough to produce disability. * patients must sign a written informed consent according with the approval of the regional ethical board of university of pécs exclusion criteria: * exclusion criteria are established in accordance to the guidelines of elble et al3. * presence of any medical conditions capable of producing tremor (e.g. hyperthyroidism, drug withdrawal, neuropathy, etc.). * except for cogwheel phenomenon, the presence of any abnormal neurological signs (e.g. dystonia, myoclonus, ataxia, parkinsonism, cerebellar or pyramidal signs, etc.) * atypical tremor appearance for et (e.g. isolated vocal-cord tremor, orthostatic tremor, task-specific tremor, etc.) * presence or suspicion of psychogenic tremor * usage of medication capable of producing tremor (e.g. sympathomimetics, valproate, etc.) * concomitant administration of any drugs potentially capable of improving et (e.g. antiepileptics, beta-receptor blockers). * previous neurosurgical treatment (e.g. deep brain stimulation or thalamotomy). * presence of serious concomitant disorders capable of interfering with the study (e.g. heart failure, tumorous disorders, etc.) * presence of any contraindication for pramipexole treatment (e.g. impulsive control disorder, known hypersensitivity to any components of the tablets, etc.)

Keywords: pramipexole essential tremor cross-over